Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Trazimera |
Synonyms | |
Therapy Description |
Trazimera (PF-05280014) is a biosimilar to the ERBB2 (HER2)-targeted monoclonal antibody Herceptin (trastuzumab), which binds to the extracellular domain of ERBB2 (HER2) and leads to decreased growth of ERBB2 (HER2)-over expressing tumor cells (PMID: 25001079, PMID: 25041377, PMID: 31798693). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Trazimera | PF-05280014 | HER2 (ERBB2) Antibody 76 | Trazimera (PF-05280014) is a biosimilar to the ERBB2 (HER2)-targeted monoclonal antibody Herceptin (trastuzumab), which binds to the extracellular domain of ERBB2 (HER2) and leads to decreased growth of ERBB2 (HER2)-over expressing tumor cells (PMID: 25001079, PMID: 25041377, PMID: 31798693). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|